Member Info for liquid1

The "killer" mask is born. It has 5 layers and the middle one can capture and neutralize incoming viruses
by Deborah Ameri

The new device was patented by British chemist Gareth Cave. Next week it will obtain the CE certification which will make it possible to sell it (at 1 euro per piece) throughout Europe. Effectiveness guaranteed for 7 consecutive hours
JANUARY 12, 2021
2 MINUTES OF READING
A mask completely similar to traditional surgical ones but with an extra weapon that could really make the difference: the ability to neutralize the Coronavirus and make it harmless .

It was invented by the British chemist Gareth Cave , in collaboration with the university where he teaches, Nottingham Trent . According to the tests conducted, the device has a filtering capacity of 99.98% and an efficiency of 90% in destroying Covid-19 and influenza viruses .

Masks and distance lower the viral load by 1000 times
by Cinzia Lucchelli
21 October 2020

How does it work

Invece dei tre strati convenzionali la nuova mascherina ne ha cinque. Il primo, quello più esterno, è fluido repellente per impedire l’inalazione di droplet, saliva e muco che potrebbero contenere il SarsCov2, il secondo e quarto sono costituiti dal tessuto filtrante presente anche in quelle chirurgiche e in mezzo a questi sta l’arma segreta: uno strato antivirale, imbevuto di nanoparticelle di rame, trattate con una tecnologia nuova, brevettata dalla Pharm2Farm, spin-ff della Nottingham Trent University e fondata proprio da Cave.

“Una volta che queste nanoparticelle sono in contatto con il virus emettono degli ioni che penetrano attraverso la superficie e avviluppano il virus distruggendo il suo materiale genetico e impedendogli di replicarsi – ci spiega il professor Cave - Queste particelle hanno forma sferica e una superficie grande quanto quella del virus e per questo sono quindi molto efficienti nell’uccidere l’ospite indesiderato, ma non nel ridurre la respirabilità della mascherina. L’ultimo strato, poi, quello più vicino alla bocca, è ipoallergenico ed estremamente traspirante”.

L’efficacia è garantita fino a 7 ore di utilizzo e il costo al pubblico è di circa un euro a mascherina.

Coronavirus, il neonato strappa la mascherina al medico
17 Ottobre 2020

Le certificazioni

I test sull’efficacia antivirale del prodotto sono stati condotti nei laboratori indipendenti del Virology Research Services di Londra, che gli ha conferito la certificazione ISO 18184 (determina i requisiti dell’attività antivirale dei prodotti tessili). “La prossima settimana otterremo il marchio CE e la mascherina potrà essere commercializzata in tutta Europa – prosegue il professore - Abbiamo da poco acquisito un macchinario per la produzione che inizierà tra qualche settimana e a febbraio potremo distribuire i primi lotti. Abbiamo già avuto richieste da diversi Paesi, Italia compresa”.

La manifattura sarà in grado di fornire fino a 5 milioni di maschere al mese.

Mascherine,

But there were far to many sellers!

When RNS lands today’s sellers can “far cough”

https://m.facebook.com/NottsTV/videos/401430187830388/

Notts TV
4 hrs ·
Masks 140121
Watch: The man behind developing a face mask that kills COVID said he is 'surprised' supermarkets have taken as long as they have to enforce mask wearing in their stores. Dr Gareth Cave, a scientist and nanotechnology expert at Nottingham Trent University, designed a face covering which uses elements of copper to kill the virus. It was hoped to be commissioned last month, but a delay in being able to obtain parts due to Brexit was one of the factors to cause a slight delay.

MN’s normally hide delayed Sell trades, NOT today.

They are hiding delayed Buys!

What do they know??!

Roll on + news

Would love to hear about Air filters from P2F.

Game changer in air con systems globally

Well this is 2.99p

Next 3.99p etc

Demand is high

NT @ 2.9p to buy

Elsewhere in its operations, P2F has now completed the initial trial of its proprietary zinc nanotechnology, with positive results, at a citrus farm in the UK. P2F will commence trials in the USA shortly and if success is replicated in the USA trials, it expects to launch this product in early 2021, for farmers to apply during the 2021 growing season. The product is part of the company's nSitu™ range of nano-agritech materials, designed to support commercial farmers around the world - in this case by helping to protect the USA's annual 8 million tons of citrus fruit crops, with an estimated value of such crops of over $3.3 billion."

https://www.investegate.co.uk/remote-monitored-sys--rms-/rns/braveheart-update-on-p2f--rms-update-on-gyrometric/202010081627535595B/

In readiness for commercial release, P2F will shortly make a patent application to protect its technology for producing the antiviral material, which it is confident could be applied to air filters, face masks and other PPE.

https://www.investegate.co.uk/remote-monitored-sys--rms-/rns/braveheart-update-on-p2f--rms-update-on-gyrometric/202010081627535595B/

Shares outstanding 1.99bn
Free float 595.31m

Market cap 53.82m GBP

https://markets.ft.com/data/equities/tearsheet/summary?s=RMS:LSE

Positive news

News over effing due

Commenting on the announcement, Dimitri Dimitriou, CEO of ImmuPharma said :

"ImmuPharma and Avion are appreciative of the FDA's fair treatment of Lupuzor(TM)'s regulatory filing under these unprecedented times due to the Covid-19 pandemic, which has put immeasurable pressure on the FDA and the industry as a whole.

"Working closely with the team at Avion we are also encouraged by their confidence in Lupuzor(TM) illustrated by asking FDA to consider a conditional approval of Lupuzor(TM) in Lupus patients, prior to completion of the new Phase 3 clinical trial. Whilst we accept that a successful consideration is only a potential possibility, on the basis that Lupuzor(TM) has demonstrated a robust safety profile, it certainly allows this to be asked. We look forward to providing further updates in due course."

The FDA offered to accept submission for a Type 'A' Meeting Request, following which, Avion submitted a full dossier on 6 November 2020 through the FDA Type 'A' route which, in normal circumstances, leads to a guidance meeting within 30 days. However, FDA timeframes cannot be guaranteed. The guidance meeting will address the key aspects of the study design, clinical end points and approval process.

In addition, Avion has asked the FDA to consider a conditional approval while the new Phase 3 is underway. A conditional approval, which would allow the marketing of Lupuzor(TM) prior to the completion of the new Phase 3, would be based on the clinically significant data previously generated in the completed Phase 2 and 3 clinical trials to date. Lupuzor(TM) is extremely safe and well tolerated, and so, whilst the Directors believe that a successful consideration is only a potential possibility, it allows this to be asked.

In anticipation of the start of the new Phase 3 clinical trial, ImmuPharma has initiated the production of a new batch of the Lupuzor(TM) drug specifically for the trial.

ImmuPharma will provide an update as soon as Avion has met with the FDA and notified ImmuPharma of the outcome.

ImmuPharma announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals (“Avion�), a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps).

Avion has exclusively in-licensed Lupuzorâ„¢ for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed.

We have always believed that ImmuPharma could deliver such a successful deal for the US market. This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of Lupuzorâ„¢.

We now see Lupuzorâ„¢ as having the ability to generate blockbuster sales in the US (£1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of £170m per year.

What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for Lupuzor™ but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for Lupuzor™, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment.

This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of Lupuzorâ„¢, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa.

Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 176p to 200p / share. BUY.

Nice!!

Mask Certification update

The test results for the certification of the Company's 4 ply mask (targeted for everyday use) are now expected to be received in the first half of January 2021.

More and more businesses are being forced to review their existing telecoms services and many are seeking new solutions which provide enhanced quality at an affordable price. We are speaking to many businesses and NGOs regarding our bespoke solutions . and the new business pipeline remains strong. We look forward to updating the market further when we announce our final results in due course."

https://www.investegate.co.uk/toople-plc--toop-/rns/new-contract-wins/202012080700038337H/

"Another key driver for Toople is the move towards at home working by small businesses and their employees. Despite the outbreak of Covid-19 and the resultant decrease in economic activity, the conditions in which Toople is set to thrive remains unaffected - and in some ways the outlook is even more positive as many people make a more permanent switch to working from home and need reliable telecommunications infrastructure. Indeed, even now the Government is tightening restrictions regarding Covid-19 and whilst this remains a challenging time for our country and many the wider business community, working from home is a key strategy that all our products and propositions support. We remain vigilant and cautious of the wider economic impact of Covid-19 while also keeping abreast of the new telecommunications possibilities that will exist in a post Covid-19 world."

Results were due December, so any time now!

The Group looks forward to updating shareholders in greater detail on these achievements in its Final Results for the year ended September 2020, expected to be announced during December 2020.

https://www.investegate.co.uk/toople-plc--toop-/rns/trading-statement/202009290700053678A/